A study of subjects with a known nickel allergy comparing Tacrolimus to placebo, both associated with nickel patches to determine the safety and efficacy of treating Chronic Allergic Contact Dermatitis with Tacrolimus Ointment
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
98
topical
topical
Unnamed facility
Washington D.C., District of Columbia, United States
Unnamed facility
Kansas City, Kansas, United States
Unnamed facility
Shawnee, Kansas, United States
Unnamed facility
Louisville, Kentucky, United States
Success using the Physician's Global Assessment (PGA)
Time frame: 8 Weeks
Investigator and subject ACD Sign and Symptoms
Time frame: 8 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
New Orleans, Louisiana, United States
Unnamed facility
Minneapolis, Minnesota, United States
Unnamed facility
New York, New York, United States
Unnamed facility
Portland, Oregon, United States
Unnamed facility
Hershey, Pennsylvania, United States
Unnamed facility
Lynchburg, Virginia, United States